Neurobiological, Empire Pharmaceuticals Inc. deal

NTII acquired Empire for cash and stock. The deal gives NTII rights to Empire's Viprinex ancrod, a perfusion therapy to treat acute ischemic stroke. NTII issued 2.4 million shares and paid $2 million ...